1
|
Argentato PP, Marchesi JAP, Dejani NN, Nakandakare PY, Teles LDFDS, Batista LPR, Leitão MPC, Luzia LA, Ramos ES, Rondó PH. The relationship between obesity-related H19DMR methylation and H19 and IGF2 gene expression on offspring growth and body composition. Front Nutr 2023; 10:1170411. [PMID: 37810933 PMCID: PMC10552537 DOI: 10.3389/fnut.2023.1170411] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Accepted: 09/04/2023] [Indexed: 10/10/2023] Open
Abstract
Background and objective Imprinted genes are important for the offspring development. To assess the relationship between obesity-related H19DMR methylation and H19 and IGF2 gene expression and offspring growth and body composition. Methods Thirty-nine overweight/obese and 25 normal weight pregnant women were selected from the "Araraquara Cohort Study" according to their pre-pregnancy BMI. Fetal growth and body composition and newborn growth were assessed, respectively, by ultrasound and anthropometry. The methylation of H19DMR in maternal blood, cord blood, maternal decidua and placental villi tissues was evaluated by methylation-sensitive restriction endonuclease qPCR, and H19 and IGF2 expression by relative real-time PCR quantification. Multiple linear regression models explored the associations of DNA methylation and gene expression with maternal, fetal, and newborn parameters. Results H19DMR was less methylated in maternal blood of the overweight/obese group. There were associations of H19DMR methylation in cord blood with centiles of fetal biparietal diameter (BPD) and abdominal subcutaneous fat thickness and newborn head circumference (HC); H19DMR methylation in maternal decidua with fetal occipitofrontal diameter (OFD), HC, and length; H19DMR methylation in placental villi with fetal OFD, HC and abdominal subcutaneous fat thickness and with newborn HC. H19 expression in maternal decidua was associated with fetal BPD and femur length centiles and in placental villi with fetal OFD and subcutaneous arm fat. IGF2 expression in maternal decidua was associated with fetal BPD and in placental villi with fetal OFD. Conclusion To our knowledge, this is the first study to demonstrate associations of imprinted genes variations at the maternal-fetal interface of the placenta and in cord blood with fetal body composition, supporting the involvement of epigenetic mechanisms in offspring growth and body composition.
Collapse
Affiliation(s)
- Perla Pizzi Argentato
- Nutrition Department, School of Public Health, University of São Paulo, São Paulo, Brazil
| | | | - Naiara Naiana Dejani
- Nutrition Department, School of Public Health, University of São Paulo, São Paulo, Brazil
| | | | | | | | | | - Liania Alves Luzia
- Nutrition Department, School of Public Health, University of São Paulo, São Paulo, Brazil
| | - Ester Silveira Ramos
- Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Patricia Helen Rondó
- Nutrition Department, School of Public Health, University of São Paulo, São Paulo, Brazil
| |
Collapse
|
2
|
Yang M, Zhang M, Wang Q, Guo X, Geng P, Gu J, Ji W, Zhang L. Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis. BMC Cancer 2023; 23:688. [PMID: 37480014 PMCID: PMC10362596 DOI: 10.1186/s12885-023-11164-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Accepted: 07/08/2023] [Indexed: 07/23/2023] Open
Abstract
BACKGROUND Numerous studies have demonstrated long noncoding RNA (lncRNA) play an important role in the occurrence and progression of cancer, and single nucleotide polymorphisms (SNPs) located in lncRNA are considered to affect cancer suspensibility. Herein, a meta-analysis was carried out to better assess the relationship of H19 polymorphisms and cancer susceptibility. METHODS A literature search was conducted through using PubMed, EMBASE, and Web of Science databases to obtain relevant publications before Aug 23, 2022. The reference lists of the retrieved studies were also investigated to identify additional relevant articles. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to appraise the risk of various cancers. RESULTS There appeared to be a remarkable correlation between the rs2107425 variation and decreased cancer risk among Caucasians. Nevertheless, the rs217727 polymorphism was significantly associated with an increased risk of lung cancer, hepatocellular carcinoma and oral squamous cell carcinoma. Also, we found a significant correlation between the rs2839698 polymorphism and increased cancer risk among Asians, gastric cancer, hepatocellular carcinoma, hospital-based control and larger simple size subgroups, respectively. Similarly, the rs3741219 mutation was notably related to cancer risk in higher quality score. As for rs3024270 polymorphism, the homozygous model was markedly linked to cancer risk in overall analysis and population-based controls. There was no significant association between the rs3741216 polymorphism and cancer risk. CONCLUSION H19 rs2839698 and rs3024270 were closely associated with overall cancer risk. H19 rs2107425 was related to lower cancer risk among Caucasians, while the rs2839698 was related to increased cancer risk among Asians. Our results supported that H19 SNPs were significantly correlated with cancer risk.
Collapse
Affiliation(s)
- Maoquan Yang
- School of Clinical Medicine, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang, Shandong, China
- Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, No. 2428, Yuhe Road, Weifang, 261031, Shandong, China
| | - Mingwei Zhang
- Department of Pathology, Shandong University School of Basic Medical Sciences, Jinan, Shandong, China
| | - Qiong Wang
- Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China
- Department of Gastroenterology, Weifang NO.2 People s Hospital, Weifang, Shandong, China
| | - Xiaojing Guo
- School of Clinical Medicine, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang, Shandong, China
| | - Peizhen Geng
- School of Clinical Medicine, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang, Shandong, China
| | - Jinhua Gu
- School of Clinical Medicine, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang, Shandong, China
| | - Wansheng Ji
- Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, No. 2428, Yuhe Road, Weifang, 261031, Shandong, China.
- Experimental Center for Medical Research, Weifang Medical University, Weifang, Shandong, China.
| | - Li Zhang
- Department of Gastroenterology, Affiliated Hospital of Weifang Medical University, No. 2428, Yuhe Road, Weifang, 261031, Shandong, China.
| |
Collapse
|
3
|
Qin M, Chen W, Hua L, Meng Y, Wang J, Li H, Yang R, Yan L, Qiao J. DNA methylation abnormalities induced by advanced maternal age in villi prime a high-risk state for spontaneous abortion. Clin Epigenetics 2023; 15:44. [PMID: 36945044 PMCID: PMC10029192 DOI: 10.1186/s13148-023-01432-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 01/20/2023] [Indexed: 03/23/2023] Open
Abstract
BACKGROUND Advanced maternal age (AMA) has increased in many high-income countries in recent decades. AMA is generally associated with a higher risk of various pregnancy complications, and the underlying molecular mechanisms are largely unknown. In the current study, we profiled the DNA methylome of 24 human chorionic villi samples (CVSs) from early pregnancies in AMA and young maternal age (YMA), 11 CVSs from early spontaneous abortion (SA) cases using reduced representation bisulfite sequencing (RRBS), and the transcriptome of 10 CVSs from AMA and YMA pregnancies with mRNA sequencing(mRNA-seq). Single-cell villous transcriptional atlas presented expression patterns of targeted AMA-/SA-related genes. Trophoblast cellular impairment was investigated through the knockdown of GNE expression in HTR8-S/Vneo cells. RESULTS AMA-induced local DNA methylation changes, defined as AMA-related differentially methylated regions (DMRs), may be derived from the abnormal expression of genes involved in DNA demethylation, such as GADD45B. These DNA methylation changes were significantly enriched in the processes involved in NOTCH signaling and extracellular matrix organization and were reflected in the transcriptional alterations in the corresponding biological processes and specific genes. Furthermore, the DNA methylation level of special AMA-related DMRs not only significantly changed in AMA but also showed more excessive defects in CVS from spontaneous abortion (SA), including four AMA-related DMRs whose nearby genes overlapped with AMA-related differentially expressed genes (DEGs) (CDK11A, C19orf71, COL5A1, and GNE). The decreased DNA methylation level of DMR near GNE was positively correlated with the downregulated expression of GNE in AMA. Single-cell atlas further revealed comparatively high expression of GNE in the trophoblast lineage, and knockdown of GNE in HTR8-S/Vneo cells significantly impaired cellular proliferation and migration. CONCLUSION Our study provides valuable resources for investigating AMA-induced epigenetic abnormalities and provides new insights for explaining the increased risks of pregnancy complications in AMA pregnancies.
Collapse
Affiliation(s)
- Meng Qin
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Wei Chen
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Lingyue Hua
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Yan Meng
- Department of Obstetrics and Gynecology, Beijing Jishuitan Hospital, Beijing, 100096, China
| | - Jing Wang
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Hanna Li
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Rui Yang
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China
| | - Liying Yan
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China.
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China.
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China.
- National Center for Healthcare Quality Management in Obstetrics, Beijing, 100191, China.
| | - Jie Qiao
- Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
- National Clinical Research Center for Obstetrics and Gynecology (Peking University Third Hospital), Beijing, 100191, China.
- Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, 100191, China.
- Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Beijing, 100191, China.
- Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, 100191, China.
- Beijing Advanced Innovation Center for Genomics, Beijing, 100871, China.
- Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
- Research Units of Comprehensive Diagnosis and Treatment of Oocyte Maturation Arrest, Beijing Jishuitan Hospital, Beijing, 100191, China.
| |
Collapse
|
4
|
Salmeri N, Carbone IF, Cavoretto PI, Farina A, Morano D. Epigenetics Beyond Fetal Growth Restriction: A Comprehensive Overview. Mol Diagn Ther 2022; 26:607-626. [PMID: 36028645 DOI: 10.1007/s40291-022-00611-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/10/2022] [Indexed: 12/30/2022]
Abstract
Fetal growth restriction is a pathological condition occurring when the fetus does not reach the genetically determined growth potential. The etiology of fetal growth restriction is expected to be multifactorial and include fetal, maternal, and placental factors, the latter being the most frequent cause of isolated fetal growth restriction. Severe fetal growth restriction has been related to both an increased risk of perinatal morbidity and mortality, and also a greater susceptibility to developing diseases (especially cardio-metabolic and neurological disorders) later in life. In the last decade, emerging evidence has supported the hypothesis of the Developmental Origin of Health and Disease, which states that individual developmental 'programming' takes place via a delicate fine tuning of fetal genetic and epigenetic marks in response to a large variety of 'stressor' exposures during pregnancy. As the placenta is the maternal-fetal interface, it has a crucial role in fetal programming, such that any perturbation altering placental function interferes with both in-utero fetal growth and also with the adult life phenotype. Several epigenetic mechanisms have been highlighted in modulating the dynamic placental epigenome, including alterations in DNA methylation status, post-translational modification of histones, and non-coding RNAs. This review aims to provide a comprehensive and critical overview of the available literature on the epigenetic background of fetal growth restriction. A targeted research strategy was performed using PubMed, MEDLINE, Embase, and The Cochrane Library up to January 2022. A detailed and fully referenced synthesis of available literature following the Scale for the Assessment of Narrative Review Articles guidelines is provided. A variety of epigenetic marks predominantly interfering with placental development, function, and metabolism were found to be potentially associated with fetal growth restriction. Available evidence on the role of environmental exposures in shaping the placental epigenome and the fetal phenotype were also critically discussed. Because of the highly dynamic crosstalk between epigenetic mechanisms and the extra level of complexity in interpreting the final placental transcriptome, a full comprehension of these phenomenon is still lacking and advances in multi-omics approaches are urgently needed. Elucidating the role of epigenetics in the developmental origins of health and disease represents a new challenge for the coming years, with the goal of providing early interventions and prevention strategies and, hopefully, new treatment opportunities.
Collapse
Affiliation(s)
- Noemi Salmeri
- Gynecology/Obstetrics Unit, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Ilma Floriana Carbone
- Unit of Obstetrics, Department of Woman, Child and Neonate, Mangiagalli Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Paolo Ivo Cavoretto
- Gynecology/Obstetrics Unit, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy
| | - Antonio Farina
- Division of Obstetrics and Prenatal Medicine, Department of Medicine and Surgery (DIMEC), IRCCS Sant'Orsola-Malpighi Hospital, University of Bologna, 40138, Bologna, Italy.
| | - Danila Morano
- Department of Morphology, Surgery and Experimental Medicine, Section of Obstetrics and Gynecology, Azienda Ospedaliero-Universitaria S. Anna, University of Ferrara, Cona, Ferrara, Italy
| |
Collapse
|
5
|
Khambata K, Raut S, Deshpande S, Mohan S, Sonawane S, Gaonkar R, Ansari Z, Datar M, Bansal V, Patil A, Warke H, Balasinor NH. DNA methylation defects in spermatozoa of male partners from couples experiencing recurrent pregnancy loss. Hum Reprod 2021; 36:48-60. [PMID: 33319906 DOI: 10.1093/humrep/deaa278] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2020] [Revised: 09/16/2020] [Indexed: 12/13/2022] Open
Abstract
STUDY QUESTION What is the sperm DNA methylation status of imprinted genes in male partners from couples experiencing recurrent pregnancy loss (RPL)? SUMMARY ANSWER Aberrations in sperm DNA methylation status of several imprinted genes, such as insulin like growth factor-2-H19 differentially methylated region (IGF2-H19 DMR), intergenic differentially methylated region (IG-DMR), mesoderm specific transcript (MEST), zinc finger protein which regulates apoptosis and cell cycle arrest (ZAC), DMR in intron 10 of KCNQ1 gene (KvDMR), paternally expressed gene 3 (PEG3) and paternally expressed gene 10 (PEG10), as well as decreased sperm global 5-methylcytosine (5mC) levels, are associated with RPL. WHAT IS KNOWN ALREADY RPL is defined as loss of two or more pregnancies, affecting 1-2% of couples of reproductive age. Although there are several maternal and paternal aetiological factors contributing to RPL, nearly 50% of the cases remain idiopathic. Thus, there is a need to identify putative paternal factors that could be contributing towards pregnancy loss in cases of idiopathic RPL. STUDY DESIGN, SIZE, DURATION In this case-control study, 112 couples undergoing RPL with no identifiable cause were recruited from September 2015 to May 2018. The control group comprised of 106 healthy proven fertile couples with no history of infertility or miscarriage. PARTICIPANTS/MATERIALS, SETTING, METHODS In this study, we investigated the paternal genetic and epigenetic factors that could be associated with RPL. We studied DNA methylation, by pyrosequencing, of selected imprinted genes implicated in embryo development, such as IGF2-H19 DMR, IG-DMR, MEST, ZAC, KvDMR, PEG3, PEG10 and small nuclear ribonucleoprotein polypeptide N (SNRPN) in sperm of men whose partners present RPL. Global DNA methylation in sperm was evaluated by studying 5mC content and long interspersed nuclear element 1 (LINE1) promoter methylation. We also studied polymorphisms by pyrosequencing in the IGF2-H19 DMR as well in the IGF2 promoter in both groups. MAIN RESULTS AND THE ROLE OF CHANCE In the RPL group, we found a significant decrease in the global sperm 5mC levels and significant decrease in DNA methylation at three CpG sites in LINE1 promoter. For IGF2-H19 DMR and IG-DMR, a significant decrease in sperm DNA methylation at specific CpG sites was observed in RPL group. For maternally imprinted genes like MEST, ZAC, KvDMR, PEG3 and PEG10 hypermethylation was noted. Polymorphism studies for IGF2-H19 DMR and IGF2 revealed significant differences in the genotypic frequencies in males. LIMITATIONS, REASONS FOR CAUTION In this study, we analysed the methylation levels of selected candidate imprinted genes implicated in embryo development. Detection of methylation changes occurring at the genome-wide level may reveal further candidate genes having a better distinction between the control and study groups. WIDER IMPLICATIONS OF THE FINDINGS Our study demonstrates that certain polymorphisms and aberrant sperm methylation status in imprinted genes are associated with RPL and could contribute to the aetiology of RPL. This study suggests that investigation of paternal genetic and epigenetic factors could be useful in identification of possible causes of idiopathic RPL. STUDY FUNDING/COMPETING INTEREST(S) This study was funded by Department of Science and Technology-Science and Engineering Research Board (EMR/2014/000145) and National Institute for Research in Reproductive Health intramural funds (RA/872/01-2020). All authors declare no conflict of interest. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- Kushaan Khambata
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Sanketa Raut
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Sharvari Deshpande
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Sweta Mohan
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Shobha Sonawane
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Reshma Gaonkar
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Zakiya Ansari
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Mamata Datar
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| | - Vandana Bansal
- Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, India
| | - Anushree Patil
- Department of Reproductive Endocrinology & Infertility, Indian Council of Medical Research-National Institute for Research in Reproductive Health (ICMR-NIRRH), Mumbai, India
| | - Himangi Warke
- Department of Obstetrics and Gynecology, Seth G. S. Medical College & King Edward Memorial Hospital (KEM), Mumbai, India
| | - Nafisa H Balasinor
- Neuroendocrinology Department, Indian Council of Medical Research-National Institute for Research in Reproductive Health, Mumbai, India
| |
Collapse
|
6
|
Dai C, Zhao C, Xu M, Sui X, Sun L, Liu Y, Su M, Wang H, Yuan Y, Zhang S, Shi J, Sun J, Li Y. Serum lncRNAs in early pregnancy as potential biomarkers for the prediction of pregnancy-induced hypertension, including preeclampsia. MOLECULAR THERAPY. NUCLEIC ACIDS 2021; 24:416-425. [PMID: 33868785 PMCID: PMC8042241 DOI: 10.1016/j.omtn.2021.03.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 03/11/2021] [Indexed: 12/30/2022]
Abstract
Long noncoding RNAs (lncRNAs) are key mediators of biological regulation with diagnostic value as disease biomarkers. We explored serum lncRNA levels in early pregnancy as potential biomarkers of pregnancy-induced hypertension (PIH), including gestational hypertension (GH) and preeclampsia (PE). We performed a two-phase nested case-control study in pregnant women before 20 weeks’ gestation (before clinical diagnosis). The screening phase assessed lncRNA expression profiles with a human lncRNA microarray in 5 pairs of serum samples (5 PE patients and 5 matched controls). The second phase validated levels of 8 candidate lncRNAs selected via the random walk method by quantitative real-time polymerase chain reaction (qRT-PCR). Serum levels of the 8 lncRNAs were markedly increased in women with PIH compared with matched normotensive pregnant (NP) women (p < 0.001), consistent with the microarray results. In addition, 7 candidate lncRNAs were correlated with PIH severity. Logistic regression analysis revealed that serum levels of ENST00000527727 (odds ratio [OR], 1.113; 95% confidence interval [CI], 1.024–1.209; p = 0.0113) and ENST00000415029 (OR, 1.126; 95% CI, 1.000–1.267; p = 0.0496) were associated with adverse pregnancy outcomes, such as fetal growth restriction (FGR) and placenta accreta of PIH. Nine pathways associated with the candidate lncRNAs had confirmed associations with PIH.
Collapse
Affiliation(s)
- Chenguang Dai
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Chenyang Zhao
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Minglu Xu
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Xinshuang Sui
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Li Sun
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Yang Liu
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Mengqi Su
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Hongling Wang
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Yue Yuan
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Song Zhang
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Jing Shi
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Jingxia Sun
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China
| | - Yue Li
- Department of Cardiology, The First Affiliated Hospital, Harbin Medical University, Harbin 150001, China.,The Cell Transplantation Key Laboratory of National Health Commission, Heilongjiang 150001, China.,Key Laboratory of Hepatosplenic Surgery, Harbin Medical University, Ministry of Education, Harbin 150001, China.,Key Laboratory of Cardiac Diseases and Heart Failure, Harbin Medical University, Harbin 150001, China.,Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Harbin 150081, China
| |
Collapse
|
7
|
Ogoyama M, Ohkuchi A, Takahashi H, Zhao D, Matsubara S, Takizawa T. LncRNA H19-Derived miR-675-5p Accelerates the Invasion of Extravillous Trophoblast Cells by Inhibiting GATA2 and Subsequently Activating Matrix Metalloproteinases. Int J Mol Sci 2021; 22:ijms22031237. [PMID: 33513878 PMCID: PMC7866107 DOI: 10.3390/ijms22031237] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 01/18/2021] [Accepted: 01/21/2021] [Indexed: 12/13/2022] Open
Abstract
The invasion of extravillous trophoblast (EVT) cells into the maternal decidua, which plays a crucial role in the establishment of a successful pregnancy, is highly orchestrated by a complex array of regulatory mechanisms. Non-coding RNAs (ncRNAs) that fine-tune gene expression at epigenetic, transcriptional, and post-transcriptional levels are involved in the regulatory mechanisms of EVT cell invasion. However, little is known about the characteristic features of EVT-associated ncRNAs. To elucidate the gene expression profiles of both coding and non-coding transcripts (i.e., mRNAs, long non-coding RNAs (lncRNAs), and microRNAs (miRNAs)) expressed in EVT cells, we performed RNA sequencing analysis of EVT cells isolated from first-trimester placentae. RNA sequencing analysis demonstrated that the lncRNA H19 and its derived miRNA miR-675-5p were enriched in EVT cells. Although miR-675-5p acts as a placental/trophoblast growth suppressor, there is little information on the involvement of miR-675-5p in trophoblast cell invasion. Next, we evaluated a possible role of miR-675-5p in EVT cell invasion using the EVT cell lines HTR-8/SVneo and HChEpC1b; overexpression of miR-675-5p significantly promoted the invasion of both EVT cell lines. The transcription factor gene GATA2 was shown to be a target of miR-675-5p; moreover, small interfering RNA-mediated GATA2 knockdown significantly promoted cell invasion. Furthermore, we identified MMP13 and MMP14 as downstream effectors of miR-675-5p/GATA2-dependent EVT cell invasion. These findings suggest that miR-675-5p-mediated GATA2 inhibition accelerates EVT cell invasion by upregulating matrix metalloproteinases.
Collapse
Affiliation(s)
- Manabu Ogoyama
- Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan; (M.O.); (A.O.); (H.T.); (S.M.)
- Department of Molecular Medicine and Anatomy, Nippon Medical School, 1-1-5 Sendagi, Tokyo 113-8602, Japan;
| | - Akihide Ohkuchi
- Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan; (M.O.); (A.O.); (H.T.); (S.M.)
| | - Hironori Takahashi
- Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan; (M.O.); (A.O.); (H.T.); (S.M.)
| | - Dongwei Zhao
- Department of Molecular Medicine and Anatomy, Nippon Medical School, 1-1-5 Sendagi, Tokyo 113-8602, Japan;
| | - Shigeki Matsubara
- Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan; (M.O.); (A.O.); (H.T.); (S.M.)
| | - Toshihiro Takizawa
- Department of Molecular Medicine and Anatomy, Nippon Medical School, 1-1-5 Sendagi, Tokyo 113-8602, Japan;
- Correspondence: ; Tel.: +81-3-3822-2131
| |
Collapse
|
8
|
Heber MF, Ptak GE. The effects of assisted reproduction technologies on metabolic health and disease†. Biol Reprod 2020; 104:734-744. [PMID: 33330924 PMCID: PMC8023432 DOI: 10.1093/biolre/ioaa224] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Revised: 11/12/2020] [Accepted: 12/04/2020] [Indexed: 12/17/2022] Open
Abstract
The increasing prevalence of metabolic diseases places a substantial burden on human health throughout the world. It is believed that predisposition to metabolic disease starts early in life, a period of great susceptibility to epigenetic reprogramming due to environmental insults. Assisted reproductive technologies (ART), i.e., treatments for infertility, may affect embryo development, resulting in multiple adverse health outcomes in postnatal life. The most frequently observed alteration in ART pregnancies is impaired placental nutrient transfer. Moreover, consequent intrauterine growth restriction and low birth weight followed by catch-up growth can all predict future obesity, insulin resistance, and chronic metabolic diseases. In this review, we have focused on evidence of adverse metabolic alterations associated with ART, which can contribute to the development of chronic adult-onset diseases, such as metabolic syndrome, type 2 diabetes, and cardiovascular disease. Due to high phenotypic plasticity, ART pregnancies can produce both offspring with adverse health outcomes, as well as healthy individuals. We further discuss the sex-specific and age-dependent metabolic alterations reflected in ART offspring, and how the degree of interference of a given ART procedure (from mild to more severe manipulation of the egg) affects the occurrence and degree of offspring alterations. Over the last few years, studies have reported signs of cardiometabolic alterations in ART offspring that are detectable at a young age but that do not appear to constitute a high risk of disease and morbidity per se. These abnormal phenotypes could be early indicators of the development of chronic diseases, including metabolic syndrome, in adulthood. The early detection of metabolic alterations could contribute to preventing the onset of disease in adulthood. Such early interventions may counteract the risk factors and improve the long-term health of the individual.
Collapse
Affiliation(s)
| | - Grażyna Ewa Ptak
- Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland.,Faculty of Biosciences, University of Teramo, Teramo, Italy
| |
Collapse
|
9
|
Li J, Quan XJ, Chen G, Hong JW, Wang Q, Xu LL, Wang BH, Yu ZH, Yu HM. PFOS-induced placental cell growth inhibition is partially mediated by lncRNA H19 through interacting with miR-19a and miR-19b. CHEMOSPHERE 2020; 261:127640. [PMID: 32738709 DOI: 10.1016/j.chemosphere.2020.127640] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Revised: 07/01/2020] [Accepted: 07/05/2020] [Indexed: 05/15/2023]
Abstract
Perfluorooctane sulfonic acid (PFOS), a persistent environmental pollutant, has been associated with decreased birth weight. The dysregulation of long non-coding RNA (lncRNA) H19 has been implicated in pregnancy complications such as intra-uterine growth retardation (IUGR), preeclampsia (PE), however, the expression and function of H19 in PFOS-exerted detrimental effects in the placenta remains to be unveiled. Here, we explored the role of H19 in PFOS-induced placental toxicity. Results showed that PFOS caused decreased cell growth in human HTR-8/SVneo cells. Expression of H19 was increased, while miR-19a and miR-19b expression were decreased in mice placenta tissues and in HTR-8/SVneo cells exposed to PFOS. A significant hypomethylation was observed at the H19 promoter in the placentas of mice that were gestational exposed to high dose of PFOS. H19 was confirmed to bind with miR-19a and miR-19b, targeting SMAD4. Furthermore, H19 appeared to partially improve the cell growth of HTR-8/SVneo cells exposed to PFOS via upregulation of miR-19a and miR-19b. In summary, our findings revealed that H19/miR-19a and miR-19b/SMAD4 axis exerted important functions in PFOS-induced placenta cell toxicity.
Collapse
Affiliation(s)
- Jing Li
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Xiao-Jie Quan
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Gang Chen
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Jia-Wei Hong
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Qi Wang
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Lin-Lin Xu
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Bing-Hua Wang
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Ze-Hua Yu
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| | - Hong-Min Yu
- School of Public Health, Xuzhou Medical College, 209 Tong-Shan Road, Xuzhou, Jiangsu, 221002, China.
| |
Collapse
|
10
|
Rousseaux S, Seyve E, Chuffart F, Bourova-Flin E, Benmerad M, Charles MA, Forhan A, Heude B, Siroux V, Slama R, Tost J, Vaiman D, Khochbin S, Lepeule J. Immediate and durable effects of maternal tobacco consumption alter placental DNA methylation in enhancer and imprinted gene-containing regions. BMC Med 2020; 18:306. [PMID: 33023569 PMCID: PMC7542140 DOI: 10.1186/s12916-020-01736-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Accepted: 08/06/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Although exposure to cigarette smoking during pregnancy has been associated with alterations of DNA methylation in the cord blood or placental cells, whether such exposure before pregnancy could induce epigenetic alterations in the placenta of former smokers has never been investigated. METHODS Our approach combined the analysis of placenta epigenomic (ENCODE) data with newly generated DNA methylation data obtained from 568 pregnant women, the largest cohort to date, either actively smoking during their pregnancy or formerly exposed to tobacco smoking. RESULTS This strategy resulted in several major findings. First, among the 203 differentially methylated regions (DMRs) identified by the epigenome-wide association study, 152 showed "reversible" alterations of DNA methylation, only present in the placenta of current smokers, whereas 26 were also found altered in former smokers, whose placenta had not been exposed directly to cigarette smoking. Although the absolute methylation changes were smaller than those observed in other contexts, such as in some congenital diseases, the observed alterations were consistent within each DMR. This observation was further supported by a demethylation of LINE-1 sequences in the placentas of both current (beta-coefficient (β) (95% confidence interval (CI)), - 0.004 (- 0.008; 0.001)) and former smokers (β (95% CI), - 0.006 (- 0.011; - 0.001)) compared to nonsmokers. Second, the 203 DMRs were enriched in epigenetic marks corresponding to enhancer regions, including monomethylation of lysine 4 and acetylation of lysine 27 of histone H3 (respectively H3K4me1 and H3K27ac). Third, smoking-associated DMRs were also found near and/or overlapping 10 imprinted genes containing regions (corresponding to 16 genes), notably including the NNAT, SGCE/PEG10, and H19/MIR675 loci. CONCLUSIONS Our results pointing towards genomic regions containing the imprinted genes as well as enhancers as preferential targets suggest mechanisms by which tobacco could directly impact the fetus and future child. The persistence of significant DNA methylation changes in the placenta of former smokers supports the hypothesis of an "epigenetic memory" of exposure to cigarette smoking before pregnancy. This observation not only is conceptually revolutionary, but these results also bring crucial information in terms of public health concerning potential long-term detrimental effects of smoking in women.
Collapse
Affiliation(s)
- Sophie Rousseaux
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Emie Seyve
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Florent Chuffart
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | | | - Meriem Benmerad
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Marie-Aline Charles
- Université de Paris, Centre for Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, Paris, France
| | - Anne Forhan
- Université de Paris, Centre for Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, Paris, France
| | - Barbara Heude
- Université de Paris, Centre for Research in Epidemiology and Statistics (CRESS), INSERM, INRAE, Paris, France
| | - Valérie Siroux
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Remy Slama
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Jorg Tost
- Laboratory for Epigenetics and Environment, Centre National de Recherche en Génomique Humaine, CEA - Institut de Biologie François Jacob, Evry, France
| | - Daniel Vaiman
- Genomics, Epigenetics and Physiopathology of Reproduction, Institut Cochin, U1016 Inserm - UMR 8104 CNRS - Paris-Descartes University, Paris, France
| | - Saadi Khochbin
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France
| | - Johanna Lepeule
- Université Grenoble Alpes, Inserm, CNRS, IAB, 38000, Grenoble, France.
| | | |
Collapse
|
11
|
Huang J, Qian Y, Cheng Q, Yang J, Ding H, Jia R. Overexpression of Long Noncoding RNA Uc.187 Induces Preeclampsia-Like Symptoms in Pregnancy Rats. Am J Hypertens 2020; 33:439-451. [PMID: 31950140 DOI: 10.1093/ajh/hpaa011] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Revised: 11/26/2019] [Accepted: 01/13/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND As a serious pregnancy-specific condition, preeclampsia (PE) is a serious pregnancy-specific condition characterized by insufficient trophoblastic invasion and shallow placental implantation. Long noncoding RNA uc.187, which is transcribed from an ultra-conserved region is highly expressed in the placental tissue of patients with PE, is associated with abnormal trophoblast invasion. Therefore, we aimed to further characterize the relationship between uc.187 and PE through in vitro experimental studies to find new targets to treat PE. METHODS In this study, we constructed PE rat models induced by lipopolysaccharide, experimented with overexpressing uc.187 and performed experiments using HTR-8/SVneo cells. RESULTS We found uc.187 was elevated in the placenta of PE rats. By injecting pregnant rats with a lentivirus containing the lncRNA uc.187, we successfully triggered maternal hypertension along with a series of symptoms similar to PE in humans. In vitro experiments demonstrated that high levels of uc.187 lead to decreased trophoblast invasion. In addition, our results revealed that uc.187 had high expression in PE and fetal growth restricted cells, but low expression in placental site trophoblastic tumors compared with the control groups. Results of western blot and cell immunofluorescence indicated that the aberrant biological behavior of HTR-8/SVneo cells were related to the distribution of β-catenin in the cytoplasm and nucleus. CONCLUSIONS Taken together, our study revealed that uc.187 was negatively correlated to trophoblastic cell invasion, and overexpression of uc.187 could induce PE-like symptoms in a pregnant rat model by affecting the distribution of β-catenin in the cytoplasm and nucleus.
Collapse
Affiliation(s)
- Jin Huang
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, China
- Fourth Clinical Medicine College, Nanjing Medical University, Nanjing, China
| | - Yating Qian
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, China
| | - Qing Cheng
- Maternal and Child Health Care Hospital of Nantong, Nantong, China
| | - Jing Yang
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, China
- Fourth Clinical Medicine College, Nanjing Medical University, Nanjing, China
| | - Hongjuan Ding
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, China
| | - Ruizhe Jia
- Nanjing Maternity and Child Health Care Hospital, Women’s Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
12
|
Vincenz C, Lovett JL, Wu W, Shedden K, Strassmann BI. Loss of Imprinting in Human Placentas Is Widespread, Coordinated, and Predicts Birth Phenotypes. Mol Biol Evol 2020; 37:429-441. [PMID: 31639821 PMCID: PMC6993844 DOI: 10.1093/molbev/msz226] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Genomic imprinting leads to mono-allelic expression of genes based on parent of origin. Therian mammals and angiosperms evolved this mechanism in nutritive tissues, the placenta, and endosperm, where maternal and paternal genomes are in conflict with respect to resource allocation. We used RNA-seq to analyze allelic bias in the expression of 91 known imprinted genes in term human placentas from a prospective cohort study in Mali. A large fraction of the imprinted exons (39%) deviated from mono-allelic expression. Loss of imprinting (LOI) occurred in genes with either maternal or paternal expression bias, albeit more frequently in the former. We characterized LOI using binomial generalized linear mixed models. Variation in LOI was predominantly at the gene as opposed to the exon level, consistent with a single promoter driving the expression of most exons in a gene. Some genes were less prone to LOI than others, particularly lncRNA genes were rarely expressed from the repressed allele. Further, some individuals had more LOI than others and, within a person, the expression bias of maternally and paternally imprinted genes was correlated. We hypothesize that trans-acting maternal effect genes mediate correlated LOI and provide the mother with an additional lever to control fetal growth by extending her influence to LOI of the paternally imprinted genes. Limited evidence exists to support associations between LOI and offspring phenotypes. We show that birth length and placental weight were associated with allelic bias, making this the first comprehensive report of an association between LOI and a birth phenotype.
Collapse
Affiliation(s)
- Claudius Vincenz
- Research Center for Group Dynamics, Institute for Social Research, University of Michigan, Ann Arbor, MI
| | - Jennie L Lovett
- Department of Anthropology, University of Michigan, Ann Arbor, MI
| | - Weisheng Wu
- BRCF Bioinformatics Core, University of Michigan, Ann Arbor, MI
| | - Kerby Shedden
- Department of Statistics, University of Michigan, Ann Arbor, MI
| | - Beverly I Strassmann
- Research Center for Group Dynamics, Institute for Social Research, University of Michigan, Ann Arbor, MI
- Department of Anthropology, University of Michigan, Ann Arbor, MI
| |
Collapse
|
13
|
|
14
|
Rutkowska K, Lukaszewicz M. Alterations to DNA structure as a cause of expression modifications of selected genes of known intrauterine-growth-restriction-association shared by chosen species - a review. Anim Genet 2019; 50:613-620. [PMID: 31571274 DOI: 10.1111/age.12861] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/02/2019] [Indexed: 12/11/2022]
Abstract
The review aimed at searching for DNA structure markers of epigenetic modifications leading to intrauterine growth restriction (IUGR) in three livestock species, mouse and human. IUGR affects mammals by harming their wellbeing and the profitability of breeding enterprises. Of the livestock species, we chose cow, pig and sheep owing to there being many reports on the epigenetics of IUGR. IUGR investigations in human and mouse are particularly numerous, as we are interested in our own wellbeing and the mouse is a model species. We decided to focus on five genes (Igf2r, Igf2, H19, Peg3 and Mest) of known IUGR association, reported in all of those species. Despite the abundance of papers on IUGR, naturally occurring mutations responsible for epigenetic modifications have been described only in human and cow. The effect of induced DNA structural modifications upon epigenetics has been described in mouse and pig. One paper regarding mouse was chosen from among those describing DNA modifications performed to obtain parthenogenetic progeny. Papers regarding pig parthenogenetic progeny described the epigenetics of genes involved in foetal development, with no interference with the genome structure. No reports on DNA modifications altering IUGR epigenetics in sheep were found. Only environmental effects were studied and we could not conclude from the experiment designs whether the gene setup could affect the expression of involved genes, as different populations were not included or not specified within particular experiments. Apparently, DNA markers of IUGR epigenetics exist. It has been reported that the small number of them, occurring naturally, may result from neglecting existing evidence of such selection or health status forecasting markers.
Collapse
Affiliation(s)
- Karolina Rutkowska
- Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, Postepu 36a, 05-552, Jastrzebiec, Poland
| | - Marek Lukaszewicz
- Institute of Genetics and Animal Breeding of the Polish Academy of Sciences, Postepu 36a, 05-552, Jastrzebiec, Poland
| |
Collapse
|
15
|
Perico N, Askenazi D, Cortinovis M, Remuzzi G. Maternal and environmental risk factors for neonatal AKI and its long-term consequences. Nat Rev Nephrol 2019; 14:688-703. [PMID: 30224767 DOI: 10.1038/s41581-018-0054-y] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Acute kidney injury (AKI) is a common and life-threatening complication in critically ill neonates. Gestational risk factors for AKI include premature birth, intrauterine growth restriction and low birthweight, which are associated with poor nephron development and are often the consequence of pre-gestational and gestational factors, such as poor nutritional status. Our understanding of how to best optimize renal development and prevent AKI is in its infancy; however, the identification of pre-gestational and gestational factors that increase the risk of adverse neonatal outcomes and the implementation of interventions, such as improving nutritional status early in pregnancy, have the potential to optimize fetal growth and reduce the risk of preterm birth, thereby improving kidney health. The overall risk of AKI among critically ill and premature neonates is exacerbated postnatally as these infants are often exposed to dehydration, septic shock and potentially nephrotoxic medications. Strategies to improve outcomes - for example, through careful evaluation of nephrotoxic drugs - may reduce the incidence of AKI and its consequences among this population. Management strategies and updated technology that will support neonates with AKI are greatly needed. Extremely premature infants and those who survive an episode of AKI should be screened for chronic kidney disease until early adulthood. Here, we provide an overview of our current understanding of neonatal AKI, focusing on its relationship to preterm birth and growth restriction. We describe factors that prevent optimal nephrogenesis during pregnancy and provide a framework for future explorations designed to maximize outcomes in this vulnerable population.
Collapse
Affiliation(s)
- Norberto Perico
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - David Askenazi
- Pediatric and Infant Center for Acute Nephrology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Monica Cortinovis
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - Giuseppe Remuzzi
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy. .,Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy. .,L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
| |
Collapse
|
16
|
Yamaguchi Y, Tayama C, Tomikawa J, Akaishi R, Kamura H, Matsuoka K, Wake N, Minakami H, Kato K, Yamada T, Nakabayashi K, Hata K. Placenta-specific epimutation at H19-DMR among common pregnancy complications: its frequency and effect on the expression patterns of H19 and IGF2. Clin Epigenetics 2019; 11:113. [PMID: 31370882 PMCID: PMC6676526 DOI: 10.1186/s13148-019-0712-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 07/22/2019] [Indexed: 12/17/2022] Open
Abstract
Background H19 and IGF2 genes are imprinted and involved in regulating fetal and placental growth. The H19 differentially methylated region (DMR) is paternally methylated and maternally unmethylated and regulates the imprinted expression of H19 and IGF2. Epimutation at the H19-DMR in humans results in congenital growth disorders, Beckwith-Wiedemann and Silver-Russell syndromes, when erroneously its maternal allele becomes methylated and its paternal allele becomes unmethylated, respectively. Although H19 and IGF2 have been assessed for their involvement in pregnancy complications including fetal growth restriction (FGR) and pregnancy-induced hypertension (PIH)/hypertensive disorder of pregnancy (HDP) intensively in the last decade, it is still not established whether epimutation at the H19-DMR in the placenta results in pathogenic conditions in pregnancy. We aimed to assess the frequency of H19-DMR epimutation and its effects on the allelic expression patterns of H19 and IGF2 genes among normal and abnormal pregnancy cases. Results We enrolled two independently collected sets of placenta samples from normal pregnancies as controls and common pregnancy complications, FGR and PIH (HDP). The first set consisted of 39 controls and 140 FGR and/or PIH cases, and the second set consisted of 29 controls and 62 cases. For these samples, we initially screened for DNA methylation changes at H19-DMR and IGF2-DMRs by combined bisulfite restriction analysis, and further analyzed cases with methylation changes for their allelic methylation and expression patterns. We identified one case each of FGR and PIH showing hypomethylation of H19-DMR and IGF2-DMRs only in the placenta, but not in cord blood, from the first case/control set. For the PIH case, we were able to determine the allelic expression pattern of H19 to be biallelically expressed and the H19/IGF2 expression ratio to be highly elevated compared to controls. We also identified a PIH case with hypomethylation at H19-DMR and IGF2-DMRs in the placenta from the second case/control set. Conclusions Placental epimutation at H19-DMR was observed among common pregnancy complication cases at the frequency of 1.5% (3 out of 202 cases examined), but not in 68 normal pregnancy cases examined. Alteration of H19/IGF2 expression patterns due to hypomethylation of H19-DMR may have been involved in the pathogenesis of pregnancy complications in these cases. Electronic supplementary material The online version of this article (10.1186/s13148-019-0712-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yuko Yamaguchi
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan.,Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Chiharu Tayama
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan
| | - Junko Tomikawa
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan
| | - Rina Akaishi
- Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, 157-8535, Japan
| | - Hiromi Kamura
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan
| | - Kentaro Matsuoka
- Department of Pathology, National Center for Child Health and Development, Tokyo, 157-8535, Japan.,Present Address: Department of Pathology, Dokkyo Medical University, Saitama Medical Center, Koshigaya, Japan
| | - Norio Wake
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Hisanori Minakami
- Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, 060-8638, Japan
| | - Kiyoko Kato
- Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
| | - Takahiro Yamada
- Clinical Genetics Unit, Kyoto University Hospital, Kyoto, 606-8507, Japan
| | - Kazuhiko Nakabayashi
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan.
| | - Kenichiro Hata
- Department of Maternal-Fetal Biology, Research Institute, National Center for Child Health and Development, Tokyo, 157-8535, Japan.
| |
Collapse
|
17
|
Bruner-Tran KL, Mokshagundam S, Barlow A, Ding T, Osteen KG. Paternal Environmental Toxicant Exposure and Risk of Adverse Pregnancy Outcomes. CURRENT OBSTETRICS AND GYNECOLOGY REPORTS 2019; 8:103-113. [PMID: 32953240 DOI: 10.1007/s13669-019-00265-w] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Purpose of Review Current clinical efforts to predict and prevent preterm birth are primarily focused on the mother and have made minimal progress in improving outcomes. However, recent data indicate that paternal factors can also influence timing of birth. Herein, we will review recent human and murine data examining the contribution of the father to pregnancy outcomes with an emphasis on environmental exposures that can negatively impact fertility and the timing of birth. Recent Findings Human epidemiology studies now clearly indicate that a variety of paternal factors (age, race, weight, smoking status) can influence sperm quality, birth timing and, in some studies, offspring health. Utilizing a mouse model, our data have 57demonstrated that developmental exposure to the environmental toxicant TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) is associated with a transgenerational reduction in sperm number and quality and an increased risk of preterm birth in an unexposed partner. Summary Toxicant exposure history can clearly influence sperm quality in men and mice. Murine data further indicate that exposures which negatively affect sperm quality also impair placental function, potentially leading to preterm birth and other adverse outcomes. Of particular concern, these changes have been linked to epigenetic alterations within the male germ cell which can then be transmitted across multiple generations. Since it is not possible to prevent an ancestral toxicant exposure in a human population, identifying lifestyle modifications that can be implemented during the preconception period to improve sperm quality should be explored for the therapeutic potential to reduce the incidence of PTB and its sequelae.
Collapse
Affiliation(s)
- Kaylon L Bruner-Tran
- Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN
| | - Shilpa Mokshagundam
- Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN
| | - Alison Barlow
- Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN
| | - Tianbing Ding
- Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN
| | - Kevin G Osteen
- Women's Reproductive Health Research Center, Department of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, TN.,Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN.,VA Tennessee Valley Healthcare System, Nashville TN
| |
Collapse
|
18
|
Wilson SL, Robinson WP. Utility of DNA methylation to assess placental health. Placenta 2018; 64 Suppl 1:S23-S28. [DOI: 10.1016/j.placenta.2017.12.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 12/12/2017] [Accepted: 12/13/2017] [Indexed: 12/18/2022]
|
19
|
Tang L, He G, Liu X, Xu W. Progress in the understanding of the etiology and predictability of fetal growth restriction. Reproduction 2018; 153:R227-R240. [PMID: 28476912 DOI: 10.1530/rep-16-0287] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2016] [Revised: 02/21/2017] [Accepted: 03/14/2017] [Indexed: 12/12/2022]
Abstract
Fetal growth restriction (FGR) is defined as the failure of fetus to reach its growth potential for various reasons, leading to multiple perinatal complications and adult diseases of fetal origins. Shallow extravillous trophoblast (EVT) invasion-induced placental insufficiency and placental dysfunction are considered the main reasons for idiopathic FGR. In this review, first we discuss the major characteristics of anti-angiogenic state and the pro-inflammatory bias in FGR. We then elaborate major abnormalities in placental insufficiency at molecular levels, including the interaction between decidual leukocytes and EVT, alteration of miRNA expression and imprinted gene expression pattern in FGR. Finally, we review current animal models used in FGR, an experimental intervention based on animal models and the progress of predictive biomarker studies in FGR.Free Chinese abstract: A Chinese translation of this abstract is freely available at http://www.reproduction-online.org/content/153/6/R215/suppl/DC1.
Collapse
Affiliation(s)
- Li Tang
- Joint Laboratory of Reproductive MedicineSCU-CUHK, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education.,Department of Obstetric and Gynecologic DiseasesWest China Second University Hospital, Sichuan University, Chengdu, People's Republic of China
| | - Guolin He
- Department of Obstetric and Gynecologic DiseasesWest China Second University Hospital, Sichuan University, Chengdu, People's Republic of China
| | - Xinghui Liu
- Department of Obstetric and Gynecologic DiseasesWest China Second University Hospital, Sichuan University, Chengdu, People's Republic of China
| | - Wenming Xu
- Joint Laboratory of Reproductive MedicineSCU-CUHK, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education .,Department of Obstetric and Gynecologic DiseasesWest China Second University Hospital, Sichuan University, Chengdu, People's Republic of China
| |
Collapse
|
20
|
Agba OB, Lausser L, Huse K, Bergmeier C, Jahn N, Groth M, Bens M, Sahm A, Gall M, Witte OW, Kestler HA, Schwab M, Platzer M. Tissue-, sex-, and age-specific DNA methylation of rat glucocorticoid receptor gene promoter and insulin-like growth factor 2 imprinting control region. Physiol Genomics 2017; 49:690-702. [PMID: 28916632 DOI: 10.1152/physiolgenomics.00009.2017] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 08/28/2017] [Accepted: 09/12/2017] [Indexed: 12/21/2022] Open
Abstract
Tissue-, sex-, and age-specific epigenetic modifications such as DNA methylation are largely unknown. Changes in DNA methylation of the glucocorticoid receptor gene (NR3C1) and imprinting control region (ICR) of IGF2 and H19 genes during the lifespan are particularly interesting since these genes are susceptible to epigenetic modifications by prenatal stress or malnutrition. They are important regulators of development and aging. Methylation changes of NR3C1 affect glucocorticoid receptor expression, which is associated with stress sensitivity and stress-related diseases predominantly occurring during aging. Methylation changes of IGF2/H19 affect growth trajectory and nutrient use with risk of metabolic syndrome. Using a locus-specific approach, we characterized DNA methylation patterns of different Nr3c1 promoters and Igf2/H19 ICR in seven tissues of rats at 3, 9, and 24 mo of age. We found a complex pattern of locus-, tissue-, sex-, and age-specific DNA methylation. Tissue-specific methylation was most prominent at the shores of the Nr3c1 CpG island (CGI). Sex-specific differences in methylation peaked at 9 mo. During aging, Nr3c1 predominantly displayed hypomethylation mainly in females and at shores, whereas hypermethylation occurred within the CGI. Igf2/H19 ICR exhibited age-related hypomethylation occurring mainly in males. Methylation patterns of Nr3c1 in the skin correlated with those in the cortex, hippocampus, and hypothalamus. Skin may serve as proxy for methylation changes in central parts of the hypothalamic-pituitary-adrenal axis and hence for vulnerability to stress- and age-associated diseases. Thus, we provide in-depth insight into the complex DNA methylation changes of rat Nr3c1 and Igf2/H19 during aging that are tissue and sex specific.
Collapse
Affiliation(s)
- Ogechukwu Brenda Agba
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
| | - Ludwig Lausser
- Systems Biology of Aging, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany.,Institute of Medical Systems Biology, Ulm University, Ulm, Germany; and
| | - Klaus Huse
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
| | - Christoph Bergmeier
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Niels Jahn
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany.,Institute of Medical Systems Biology, Ulm University, Ulm, Germany; and.,Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Marco Groth
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
| | - Martin Bens
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
| | - Arne Sahm
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany
| | - Maria Gall
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Otto W Witte
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Hans A Kestler
- Systems Biology of Aging, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany.,Institute of Medical Systems Biology, Ulm University, Ulm, Germany; and
| | - Matthias Schwab
- Hans Berger Department of Neurology, Jena University Hospital, Jena, Germany
| | - Matthias Platzer
- Genome Analysis, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany;
| |
Collapse
|
21
|
Lin Y, Fu F, Chen Y, Qiu W, Lin S, Yang P, Huang M, Wang C. Genetic variants in long noncoding RNA H19 contribute to the risk of breast cancer in a southeast China Han population. Onco Targets Ther 2017; 10:4369-4378. [PMID: 28919786 PMCID: PMC5593399 DOI: 10.2147/ott.s127962] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The long noncoding RNA (lncRNA) H19 is a maternally expressed imprinted gene that plays important roles in tumorigenesis, progression, and metastasis. However, the association between polymorphisms on H19 and breast cancer (BC) susceptibility has remained obscure. In this case–control study, we assessed the interaction between two lncRNA H19 single-nucleotide polymorphisms (SNPs) (rs217727 C>T, rs2839698 C>T) and the risk of BC in a Chinese Han population. In total, 1,005 BC cases and 1,020 healthy controls were enrolled in this study. Correlations between genotypes and BC risk were evaluated by multivariate logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs). False-positive report probability calculation was also utilized to identify false-positive associations. We observed that the rs217727 T variant was consistently significantly associated with an increased risk of BC in both codominant and dominant models (CT vs CC, OR 1.25, 95% CI 1.03–1.51; TT vs CC, OR 1.56, 95% CI 1.15–2.09; CT + TT vs CC, OR 1.31, 95% CI 1.09–1.57), and all associations remained significant after Bonferroni correction (P<0.025). Subsequent stratified analyses also revealed that associations between BC risk and rs217727 genotypes were more profound in patients with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, and hormone receptor-positive–HER2-negative molecular subtypes (all passed the threshold for Bonferroni correction, P<0.005). These findings extend available data on the association of H19 polymorphisms and BC susceptibility. Based on these results, we encourage further large-scale studies and functional research to confirm our findings and better elucidate the underlying biological mechanisms.
Collapse
Affiliation(s)
- Yuxiang Lin
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Fangmeng Fu
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Yazhen Chen
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Wei Qiu
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Songping Lin
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Peidong Yang
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| | - Meng Huang
- Fujian Center for Disease Control and Prevention, Fuzhou, China
| | - Chuan Wang
- Department of Breast Surgery, Affiliated Union Hospital of Fujian Medical University
| |
Collapse
|
22
|
Piyasena C, Reynolds RM, Khulan B, Seckl JR, Menon G, Drake AJ. Placental 5-methylcytosine and 5-hydroxymethylcytosine patterns associate with size at birth. Epigenetics 2016; 10:692-7. [PMID: 26091021 PMCID: PMC4623028 DOI: 10.1080/15592294.2015.1062963] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Altered placental function as a consequence of aberrant imprinted gene expression may be one mechanism mediating the association between low birth weight and increased cardiometabolic disease risk. Imprinted gene expression is regulated by epigenetic mechanisms, particularly DNA methylation (5mC) at differentially methylated regions (DMRs). While 5-hydroxymethylcytosine (5hmC) is also present at DMRs, many techniques do not distinguish between 5mC and 5hmC. Using human placental samples, we show that the expression of the imprinted gene CDKN1C associates with birth weight. Using specific techniques to map 5mC and 5hmC at DMRs controlling the expression of CDKN1C and the imprinted gene IGF2, we show that 5mC enrichment at KvDMR and DMR0, and 5hmC enrichment within the H19 gene body, associate positively with birth weight. Importantly, the presence of 5hmC at imprinted DMRs may complicate the interpretation of DNA methylation studies in placenta; future studies should consider using techniques that distinguish between, and permit quantification of, both modifications.
Collapse
Affiliation(s)
- Chinthika Piyasena
- a University/British Heart Foundation Center for Cardiovascular Science; University of Edinburgh; The Queen's Medical Research Institute ; Edinburgh , UK
| | | | | | | | | | | |
Collapse
|
23
|
Hua Q, Lv X, Gu X, Chen Y, Chu H, Du M, Gong W, Wang M, Zhang Z. Genetic variants in lncRNAH19are associated with the risk of bladder cancer in a Chinese population. Mutagenesis 2016; 31:531-8. [DOI: 10.1093/mutage/gew018] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
24
|
Nielsen HM, How-Kit A, Guerin C, Castinetti F, Vollan HKM, De Micco C, Daunay A, Taieb D, Van Loo P, Besse C, Kristensen VN, Hansen LL, Barlier A, Sebag F, Tost J. Copy number variations alter methylation and parallel IGF2 overexpression in adrenal tumors. Endocr Relat Cancer 2015; 22:953-67. [PMID: 26400872 PMCID: PMC4621769 DOI: 10.1530/erc-15-0086] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/22/2015] [Indexed: 12/14/2022]
Abstract
Overexpression of insulin growth factor 2 (IGF2) is a hallmark of adrenocortical carcinomas and pheochromocytomas. Previous studies investigating the IGF2/H19 locus have mainly focused on a single molecular level such as genomic alterations or altered DNA methylation levels and the causal changes underlying IGF2 overexpression are still not fully established. In the current study, we analyzed 62 tumors of the adrenal gland from patients with Conn's adenoma (CA, n=12), pheochromocytomas (PCC, n=10), adrenocortical benign tumors (ACBT, n=20), and adrenocortical carcinomas (ACC, n=20). Gene expression, somatic copy number variation of chr11p15.5, and DNA methylation status of three differential methylated regions of the IGF2/H19 locus including the H19 imprinting control region were integratively analyzed. IGF2 overexpression was found in 85% of the ACCs and 100% of the PCCs compared to 23% observed in CAs and ACBTs. Copy number aberrations of chr11p15.5 were abundant in both PCCs and ACCs but while PCCs retained a diploid state, ACCs were frequently tetraploid (7/19). Loss of either a single allele or loss of two alleles of the same parental origin in tetraploid samples resulted in a uniparental disomy-like genotype. These copy number changes correlated with hypermethylation of the H19 ICR suggesting that the lost alleles were the unmethylated maternal alleles. Our data provide conclusive evidence that loss of the maternal allele correlates with IGF2 overexpression in adrenal tumors and that hypermethylation of the H19 ICR is a consequence thereof.
Collapse
Affiliation(s)
- Helene Myrtue Nielsen
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty
| | - Alexandre How-Kit
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Carole Guerin
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Frederic Castinetti
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Hans Kristian Moen Vollan
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty
| | - Catherine De Micco
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Antoine Daunay
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - David Taieb
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Peter Van Loo
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty
| | - Celine Besse
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Vessela N Kristensen
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty
| | - Lise Lotte Hansen
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Anne Barlier
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Frederic Sebag
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| | - Jörg Tost
- Laboratory for Functional GenomicsFondation Jean Dausset - Centre d'Etude du Polymorphisme Humain (CEPH), Paris, FranceInstitute of BiomedicineAarhus University, Aarhus, DenmarkEndocrine and Metabolic Surgery DepartmentAP-HM La Conception, Marseille, FranceDepartment of EndocrinologyAP-HM La Timone, Marseille, FranceDepartment of GeneticsInstitute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, NorwayDivision of SurgeryTransplantation and Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, NorwayThe K G Jebsen Center for Breast Cancer ResearchInstitute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, NorwayPathology DepartmentAP-HM La Timone, Marseille, FranceNuclear Endocrine Imaging and Treatment DepartmentAP-HM La Timone, Marseille, FranceCancer Research UKLondon Research Institute, London, UKDepartment of Human GeneticsUniversity of Leuven, Leuven, BelgiumGenotyping FacilitiesCentre National de Génotypage, CEA-Institut de Génomique, Evry, FranceDepartment of Clinical Molecular Biology (EpiGen)University of Oslo, Ahus, Lokerod, NorwayLaboratory of Molecular BiologyAP-HM La Conception and CRN2M, Aix-Marseille University, Marseille, FranceLaboratory for Epigenetics and EnvironmentCentre National de Génotypage, CEA-Institut de Génomique, Evry, France
| |
Collapse
|
25
|
Januar V, Desoye G, Novakovic B, Cvitic S, Saffery R. Epigenetic regulation of human placental function and pregnancy outcome: considerations for causal inference. Am J Obstet Gynecol 2015; 213:S182-96. [PMID: 26428498 DOI: 10.1016/j.ajog.2015.07.011] [Citation(s) in RCA: 81] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Revised: 07/03/2015] [Accepted: 07/13/2015] [Indexed: 12/14/2022]
Abstract
Epigenetic mechanisms, often defined as regulating gene activity independently of underlying DNA sequence, are crucial for healthy development. The sum total of epigenetic marks within a cell or tissue (the epigenome) is sensitive to environmental influence, and disruption of the epigenome in utero has been associated with adverse pregnancy outcomes. Not surprisingly, given its multifaceted functions and important role in regulating pregnancy outcome, the placenta shows unique epigenetic features. Interestingly however, many of these are only otherwise seen in human malignancy (the pseudomalignant placental epigenome). Epigenetic variation in the placenta is now emerging as a candidate mediator of environmental influence on placental functioning and a key regulator of pregnancy outcome. However, replication of findings is generally lacking, most likely due to small sample sizes and a lack of standardization of analytical approaches. Defining DNA methylation "signatures" in the placenta associated with maternal and fetal outcomes offers tremendous potential to improve pregnancy outcomes, but care must be taken in interpretation of findings. Future placental epigenetic research would do well to address the issues present in epigenetic epidemiology more generally, including careful consideration of sample size, potentially confounding factors, issues of tissue heterogeneity, reverse causation, and the role of genetics in modulating epigenetic profile. The importance of animal or in vitro models in establishing a functional role of epigenetic variation identified in human beings, which is key to establishing causation, should not be underestimated.
Collapse
Affiliation(s)
- Vania Januar
- Cancer and Disease Epigenetics, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Australia
| | - Gernot Desoye
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Boris Novakovic
- Cancer and Disease Epigenetics, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Australia
| | - Silvija Cvitic
- Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
| | - Richard Saffery
- Cancer and Disease Epigenetics, Murdoch Childrens Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Pediatrics, University of Melbourne, Parkville, Australia.
| |
Collapse
|
26
|
Distinct promoter methylation and isoform-specific expression of RASFF1A in placental biopsies from complicated pregnancies. Placenta 2015; 36:397-402. [DOI: 10.1016/j.placenta.2015.01.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Revised: 12/20/2014] [Accepted: 01/21/2015] [Indexed: 01/13/2023]
|
27
|
Bian EB, Li J, Xie YS, Zong G, Li J, Zhao B. LncRNAs: New Players in Gliomas, With Special Emphasis on the Interaction of lncRNAs With EZH2. J Cell Physiol 2014; 230:496-503. [PMID: 24403021 DOI: 10.1002/jcp.24549] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Accepted: 12/20/2013] [Indexed: 12/14/2022]
Affiliation(s)
- Er-Bao Bian
- Department of Neurosurgery; The Second Affiliated Hospital of Anhui Medical University; Hefei China
- Cerebral Vascular Disease Research Center; Anhui Medical University; Hefei China
| | - Jia Li
- Department of Neurosurgery; The Second Affiliated Hospital of Anhui Medical University; Hefei China
- Cerebral Vascular Disease Research Center; Anhui Medical University; Hefei China
| | - Yong-Sheng Xie
- Department of Neurosurgery; The Second Affiliated Hospital of Anhui Medical University; Hefei China
- Cerebral Vascular Disease Research Center; Anhui Medical University; Hefei China
| | - Gang Zong
- Department of Neurosurgery; The Second Affiliated Hospital of Anhui Medical University; Hefei China
- Cerebral Vascular Disease Research Center; Anhui Medical University; Hefei China
| | - Jun Li
- School of Pharmacy; Anhui Medical University; Hefei China
| | - Bing Zhao
- Department of Neurosurgery; The Second Affiliated Hospital of Anhui Medical University; Hefei China
- Cerebral Vascular Disease Research Center; Anhui Medical University; Hefei China
| |
Collapse
|
28
|
Shin HS, Seo JH, Jeong SH, Park SW, Park Y, Son SW, Kim JS, Kang HG. Exposure of pregnant mice to chlorpyrifos-methyl alters embryonic H19 gene methylation patterns. ENVIRONMENTAL TOXICOLOGY 2014; 29:926-935. [PMID: 23125134 DOI: 10.1002/tox.21820] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Revised: 09/11/2012] [Accepted: 09/23/2012] [Indexed: 06/01/2023]
Abstract
The aim of this study was to identify whether chlorpyrifos methyl (CPM) exposure during pregnancy leads to changes in the methylation patterns of H19 gene. CPM 4, 20, 100 mg/kg bw/day was administered to 4 pregnant mice per group between 7 and 12 days post coitum (d.p.c.). Pregnant mice were killed at 13 d.p.c. The genomic methylation in primordial germ cells (PGCs) and fetal organs (the liver, intestine, and placenta) was examined. Four polymorphism sites in the H19 alleles of maternal (C57BL/6J) and paternal (CAST/Ei) alleles were identified at nucleotide position 1407, 1485, 1566, and 1654. The methylation patterns of 17 CpG sites were analyzed. The methylation level in male and female PGCs was not altered by CPM treatment in the maternal allele H19. The methylation level of the paternal H19 allele was altered in only male PGCs in response to the CPM treatment. The methylation level at a binding site for the transcriptional regulator CTCF2 was higher than that at the CTCF1 binding site in all CPM-treated groups. In the placenta, the aggregate methylation level of H19 was 56.89%in control group. But, those levels were ranged from 47.7% to 49.89% after treatment with increasing doses of CPM. H19 gene from the liver and intestine of 13 d.p.c. fetuses treated with CPM was hypomethylated as compared with controls, although H19 mRNA expression was unaltered. In the placenta, H19 expression was slightly increased in the CPM-treated group, although not significantly. IGF2 expression levels were not significantly changed in the placenta. In conclusion, CPM exposure during pregnancy alters the methylation status of the H19 gene in PGCs and embryonic tissues. We infer that these alterations are likely related to changes in DNA demethylase activity.
Collapse
Affiliation(s)
- Hyo-Sook Shin
- Toxicology & Residue Chemistry Division, Animal, Plant and Fisheries Quarantine and Inspection Agency, 175 Anyangro, Anyang-si, Gyeonggi-do 430-757, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Jiang H, Yu Y, Xun P, Zhang J, Luo G, Wang Q. Maternal mRNA expression levels of H19 are inversely associated with risk of macrosomia. Arch Med Sci 2014; 10:525-30. [PMID: 25097584 PMCID: PMC4107258 DOI: 10.5114/aoms.2014.43746] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2011] [Revised: 02/11/2012] [Accepted: 04/01/2012] [Indexed: 01/02/2023] Open
Abstract
INTRODUCTION To investigate the associations between the mRNA levels of H19 in term placenta and risk of macrosomia. MATERIAL AND METHODS Term placentas were collected from 37 macrosomia and 37 matched neonates with normal birth weight (controls) born in Changzhou Women and Children Health Hospital, Jiangsu province, P. R. China from March 1 to June 30, 2008. The mRNA levels of H19 in those placentas were measured by real-time polymerase chain reaction (PCR). Simple and multiple logistic regression models were used to explore the risk factors in the development of macrosomia. All analyses were performed using Stata 10.0 (StataCorp, College Station, Texas, USA). RESULTS The average H19 mRNA level of the macrosomia group was 1.450 ±0.456 while in the control group it was 2.080 ±1.296. Based on the result of Student's t test, there was a significant difference in H19 mRNA level between the macrosomia group and the control group (p = 0.008). After controlling for potential confounders, the multivariable adjusted odds ratio (OR) of macrosomia for those in the highest tertile of H19 mRNA level was 0.12 (95% CI: 0.02-0.59) when compared to those in the lowest tertile (p for linear trend = 0.009). CONCLUSIONS The term placental H19 mRNA levels were inversely related to the occurrence of macrosomia. Our findings suggest that the low expression of H19 mRNA may contribute to the development of macrosomia.
Collapse
Affiliation(s)
- Hua Jiang
- Changzhou Maternity and Child Health Hospital Affiliated to Nanjing Medical University Jiangsu, China
| | - Yang Yu
- Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
| | - Pengcheng Xun
- Department of Nutrition, Gillings Schools of Global Public Health and School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
- Department of Epidemiology, Gillings Schools of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, USA
| | - Jun Zhang
- Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
| | - Guanghua Luo
- Comprehensive Laboratory, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China
| | - Qiuwei Wang
- Changzhou Maternity and Child Health Hospital Affiliated to Nanjing Medical University Jiangsu, China
| |
Collapse
|
30
|
Yin YZ, She Q, Zhang J, Zhang PZ, Zhang Y, Lin JW, Ye YC. Placental methylation markers in normal and trisomy 21 tissues. Prenat Diagn 2013; 34:63-70. [PMID: 24166080 DOI: 10.1002/pd.4256] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 09/08/2013] [Accepted: 10/09/2013] [Indexed: 11/06/2022]
Abstract
OBJECTIVE The objective of this study is to combine multiplex ligation-dependent probe amplification (MLPA) and bisulfite sequencing to determine DNA methylation markers for noninvasive prenatal diagnosis of Down syndrome. METHODS DNA methylation ratios (MR) of four fragments (CGI149, CGI045, HLCS-1, and HLCS-2) on chromosome 21 were evaluated in blood cells from 13 nonpregnant women, 15 euploidies, and 11 Down Syndrome (DS) placentae. Ratios were measured by bisulfite sequencing and methylation-specific (MS)-MLPA. RESULTS The MS-MLPA and bisulfite sequencing results were concordant. CGI149, CGI045, and HLCS-2 were unmethylated in all nonpregnant blood cells. CGI149, CGI045, HLCS-1, and HLCS-2 were methylated in most of the euploid (13, 11, 15, and 15, respectively) and DS placentae (10, 11, 11, and 11, respectively). The median placental DNA MR in CGI149 was 0.4578 (interquartile range, 0.3568-0.5169) and 0.5918 (interquartile range, 0.5618-0.6659) in euploid and DS placentae, respectively (p = 0.001). Using placental MR at 0.5390 as a threshold, we detected DS at 90.9% sensitivity and 93.3% specificity. CONCLUSION The MS-MLPA is an effective alternative to bisulfite sequencing in assessing placental MR. CGI149 is a potential marker for the noninvasive diagnosis of Down syndrome.
Collapse
Affiliation(s)
- Yu-Zhu Yin
- Department of Obstetrics and Gynecology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
| | | | | | | | | | | | | |
Collapse
|
31
|
Chaiworapongsa T, Romero R, Whitten A, Tarca AL, Bhatti G, Draghici S, Chaemsaithong P, Miranda J, Kim CJ, Hassan SS. Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med 2013; 41:485-504. [PMID: 23793063 PMCID: PMC4164302 DOI: 10.1515/jpm-2013-0082] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2013] [Accepted: 05/15/2013] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Preeclampsia (PE) can be sub-divided into early- and late-onset phenotypes. The pathogenesis of these two phenotypes has not been elucidated. To gain insight into the mechanisms of disease, the transcriptional profiles of whole blood from women with early- and late-onset PE were examined. METHODS A cross-sectional study was conducted to include women with: i) early-onset PE (diagnosed prior to 34 weeks, n=25); ii) late-onset PE (after 34 weeks, n=47); and iii) uncomplicated pregnancy (n=61). Microarray analysis of mRNA expression in peripheral whole blood was undertaken using Affymetrix microarrays. Differential gene expression was evaluated using a moderated t-test (false discovery rate <0.1 and fold change >1.5), adjusting for maternal white blood cell count and gestational age. Validation by real-time qRT-PCR was performed in a larger sample size [early PE (n=31), late PE (n=72) and controls (n=99)] in all differentially expressed genes. Gene ontology analysis and pathway analysis were performed. RESULTS i) 43 and 28 genes were differentially expressed in early- and late-onset PE compared to the control group, respectively; ii) qRT-PCR confirmed the microarray results for early and late-onset PE in 77% (33/43) and 71% (20/28) of genes, respectively; iii) 20 genes that are involved in coagulation (SERPINI2), immune regulation (VSIG4, CD24), developmental process (H19) and inflammation (S100A10) were differentially expressed in early-onset PE alone. In contrast, only seven genes that encoded proteins involved in innate immunity (LTF, ELANE) and cell-to-cell recognition in the nervous system (CNTNAP3) were differentially expressed in late-onset PE alone. Thirteen genes that encode proteins involved in host defense (DEFA4, BPI, CTSG, LCN2), tight junctions in blood-brain barrier (EMP1) and liver regeneration (ECT2) were differentially expressed in both early- and late-onset PE. CONCLUSION Early- and late-onset PE are characterized by a common signature in the transcriptional profile of whole blood. A small set of genes were differentially regulated in early- and late-onset PE. Future studies of the biological function, expression timetable and protein expression of these genes may provide insight into the pathophysiology of PE.
Collapse
Affiliation(s)
| | - Roberto Romero
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA
| | - Amy Whitten
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA,Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA
| | - Adi L Tarca
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA,Department of Computer Science, Wayne State University, Detroit, MI, USA
| | - Gaurav Bhatti
- Department of Computer Science, Wayne State University, Detroit, MI, USA
| | - Sorin Draghici
- Department of Computer Science, Wayne State University, Detroit, MI, USA
| | - Piya Chaemsaithong
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA,Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA
| | - Jezid Miranda
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA,Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA
| | - Chong Jai Kim
- Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
| | - Sonia S Hassan
- Perinatology Research Branch, NICHD, NIH, DHHS, Detroit, MI, and Bethesda, Maryland, USA,Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI, USA
| |
Collapse
|
32
|
Reynolds RM, Jacobsen GH, Drake AJ. What is the evidence in humans that DNA methylation changes link events in utero and later life disease? Clin Endocrinol (Oxf) 2013; 78:814-22. [PMID: 23374091 DOI: 10.1111/cen.12164] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Revised: 11/30/2012] [Accepted: 01/29/2013] [Indexed: 01/23/2023]
Abstract
Development in utero is now recognized as crucial to determining later life disease susceptibility. Whilst mechanisms are poorly understood, there has been considerable interest in the potential role of epigenetic processes in intra-uterine programming of disease. Epigenetic modifications include various mechanisms that influence chromatin structure and gene expression. Here, we review emerging data from human studies that altered DNA methylation links intra-uterine events with later life disease. Further research in this field is needed to determine whether altered DNA methylation in target tissues can be used as a biomarker for the early identification of and intervention in individuals most at risk of later life disease.
Collapse
Affiliation(s)
- Rebecca M Reynolds
- Endocrinology Unit, University/BHF Centre for Cardiovascular Sciences, Queen's Medical Research Institute, Edinburgh, UK.
| | | | | |
Collapse
|
33
|
Abstract
PURPOSE OF REVIEW Intrauterine growth restriction (IUGR) occurs when fetal growth rate falls below the genetic potential and affects a significant number of pregnancies, but still no therapy has been developed for this pregnancy disease. This article reviews the most recent findings concerning maternal characteristics and behaviours predisposing to IUGR as well as maternal early markers of the disease. A comprehensive understanding of factors associated with IUGR will help in providing important tools for preventing and understanding adverse outcomes. RECENT FINDINGS Maternal nutritional status, diet and exposure to environmental factors are increasingly acknowledged as potential factors affecting fetal growth both by altering nutrient availability to the fetus and by modulating placental gene expression, thus modifying placental function. SUMMARY Assessing nutritional and environmental factors associated with IUGR, and the molecular mechanisms by which they may have a role in the disease onset, is necessary to provide comprehensive and common guidelines for maternal care and recommended behaviours. Moreover, maternal genetic predispositions and early serum markers may allow a better and more specific monitoring of high risk pregnancies, optimizing the timing of delivery.
Collapse
Affiliation(s)
- Irene Cetin
- Department of Biomedical and Clinical Sciences L.Sacco, University of Milan, Milan, Italy.
| | | | | |
Collapse
|
34
|
Novakovic B, Gordon L, Robinson WP, Desoye G, Saffery R. Glucose as a fetal nutrient: dynamic regulation of several glucose transporter genes by DNA methylation in the human placenta across gestation. J Nutr Biochem 2013; 24:282-8. [DOI: 10.1016/j.jnutbio.2012.06.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Revised: 05/10/2012] [Accepted: 06/08/2012] [Indexed: 01/02/2023]
|
35
|
Novakovic B, Saffery R. The ever growing complexity of placental epigenetics – Role in adverse pregnancy outcomes and fetal programming. Placenta 2012; 33:959-70. [DOI: 10.1016/j.placenta.2012.10.003] [Citation(s) in RCA: 79] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2012] [Revised: 10/02/2012] [Accepted: 10/06/2012] [Indexed: 02/01/2023]
|
36
|
Ptak GE, D'Agostino A, Toschi P, Fidanza A, Zacchini F, Czernik M, Monaco F, Loi P. Post-implantation mortality of in vitro produced embryos is associated with DNA methyltransferase 1 dysfunction in sheep placenta. Hum Reprod 2012; 28:298-305. [DOI: 10.1093/humrep/des397] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
37
|
Wang KCW, Botting KJ, Padhee M, Zhang S, McMillen IC, Suter CM, Brooks DA, Morrison JL. Early origins of heart disease: Low birth weight and the role of the insulin-like growth factor system in cardiac hypertrophy. Clin Exp Pharmacol Physiol 2012; 39:958-64. [DOI: 10.1111/j.1440-1681.2012.05743.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Kimberley CW Wang
- Early Origins of Adult Health Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| | | | - Monalisa Padhee
- Early Origins of Adult Health Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| | - Song Zhang
- Early Origins of Adult Health Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| | - I Caroline McMillen
- Early Origins of Adult Health Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| | - Catherine M Suter
- Victor Chang Cardiac Research Institute; Darlinghurst; New South Wales; Australia
| | - Doug A Brooks
- Cell Biology of Diseases Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| | - Janna L Morrison
- Early Origins of Adult Health Research Group; Sansom Institute for Health Research; School of Pharmacy and Medical Sciences; University of Adelaide; Adelaide; South Australia; Australia
| |
Collapse
|
38
|
Vaughan OR, Sferruzzi-Perri AN, Coan PM, Fowden AL. Environmental regulation of placental phenotype: implications for fetal growth. Reprod Fertil Dev 2012; 24:80-96. [PMID: 22394720 DOI: 10.1071/rd11909] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Environmental conditions during pregnancy determine birthweight, neonatal viability and adult phenotype in human and other animals. In part, these effects may be mediated by the placenta, the principal source of nutrients for fetal development. However, little is known about the environmental regulation of placental phenotype. Generally, placental weight is reduced during suboptimal conditions like maternal malnutrition or hypoxaemia but compensatory adaptations can occur in placental nutrient transport capacity to help maintain fetal growth. In vivo studies show that transplacental glucose and amino acid transfer adapt to the prevailing conditions induced by manipulating maternal calorie intake, dietary composition and hormone exposure. These adaptations are due to changes in placental morphology, metabolism and/or abundance of specific nutrient transporters. This review examines environmental programming of placental phenotype with particular emphasis on placental nutrient transport capacity and its implications for fetal growth, mainly in rodents. It also considers the systemic, cellular and molecular mechanisms involved in signalling environmental cues to the placenta. Ultimately, the ability of the placenta to balance the competing interests of mother and fetus in resource allocation may determine not only the success of pregnancy in producing viable neonates but also the long-term health of the offspring.
Collapse
Affiliation(s)
- O R Vaughan
- Centre for Trophoblast Research, Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK.
| | | | | | | |
Collapse
|
39
|
Cortessis VK, Thomas DC, Levine AJ, Breton CV, Mack TM, Siegmund KD, Haile RW, Laird PW. Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships. Hum Genet 2012; 131:1565-89. [PMID: 22740325 PMCID: PMC3432200 DOI: 10.1007/s00439-012-1189-8] [Citation(s) in RCA: 194] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2012] [Accepted: 06/07/2012] [Indexed: 12/15/2022]
Abstract
Changes in epigenetic marks such as DNA methylation and histone acetylation are associated with a broad range of disease traits, including cancer, asthma, metabolic disorders, and various reproductive conditions. It seems plausible that changes in epigenetic state may be induced by environmental exposures such as malnutrition, tobacco smoke, air pollutants, metals, organic chemicals, other sources of oxidative stress, and the microbiome, particularly if the exposure occurs during key periods of development. Thus, epigenetic changes could represent an important pathway by which environmental factors influence disease risks, both within individuals and across generations. We discuss some of the challenges in studying epigenetic mediation of pathogenesis and describe some unique opportunities for exploring these phenomena.
Collapse
Affiliation(s)
- Victoria K. Cortessis
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089 USA
| | - Duncan C. Thomas
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto St., SSB-202F, Los Angeles, CA 90089-9234 USA
| | - A. Joan Levine
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089 USA
| | - Carrie V. Breton
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto St., Los Angeles, CA 90089-9234 USA
| | - Thomas M. Mack
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089 USA
| | - Kimberly D. Siegmund
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 2001 N. Soto St., Los Angeles, CA 90089-9234 USA
| | - Robert W. Haile
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089 USA
| | - Peter W. Laird
- Departments of Surgery, Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, USC Norris Comprehensive Cancer Center, Epigenome Center, 1441 Eastlake Avenue, Los Angeles, CA 90089-9601 USA
| |
Collapse
|
40
|
Kim SY, Romero R, Tarca AL, Bhatti G, Kim CJ, Lee J, Elsey A, Than NG, Chaiworapongsa T, Hassan SS, Kang GH, Kim JS. Methylome of fetal and maternal monocytes and macrophages at the feto-maternal interface. Am J Reprod Immunol 2012; 68:8-27. [PMID: 22385097 DOI: 10.1111/j.1600-0897.2012.01108.x] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2011] [Accepted: 01/19/2012] [Indexed: 11/28/2022] Open
Abstract
PROBLEM Decidual macrophages (dMφ) of the mother and placental macrophages (Hofbauer cells, HC) of the fetus are deployed at a critical location: the feto-maternal interface. This study was conducted to compare the DNA methylome of maternal and fetal monocytes, dMφ, and HC and thereby to determine the immunobiological importance of DNA methylation in pregnancy. METHOD OF STUDY Paired samples were obtained from normal pregnant women at term not in labor and their neonates. Maternal monocytes (MMo) and fetal monocytes (FMo) were isolated from the peripheral blood of mothers and fetal cord blood, respectively. dMφ and HC were obtained from the decidua of fetal membranes and placentas, respectively. DNA methylation profiling was performed using the Illumina Infinium Human Methylation27 BeadChip. Quantitative real-time PCR and Western Blot were performed for validation experiments. RESULTS (i) Significant differences in DNA methylation were found in each comparison (MMo versus FMo, 65 loci; dMφ versus HC, 266 loci; MMo versus dMφ, 199 loci; FMo versus HC, 1030 loci). (ii) Many of the immune response-related genes were hypermethylated in fetal cells (FMo and HC) compared to maternal cells (MMo and dMφ). (iii) Genes encoding markers of classical macrophage activation were hypermethylated, and genes encoding alternative macrophage activation were hypomethylated in dMφ and HC compared to MMo and FMo, respectively. (iv) mRNA expressions of DNMT1, DNMT3A, and DNMT3B were significantly lower in dMφ than in HC. (v) 5-azacytidine treatment increased expression of INCA1 in dMφ. CONCLUSIONS The findings herein indicate that DNA methylation patterns change during monocyte-macrophage differentiation at the feto-maternal interface. It is also suggested that DNA methylation is an important component of the biological machinery conferring an anti-inflammatory phenotype to macrophages at the feto-maternal interface.
Collapse
Affiliation(s)
- Sun Young Kim
- Perinatology Research Branch, NICHD/NIH/DHHS, Detroit, MI 48201, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Koukoura O, Sifakis S, Spandidos DA. DNA methylation in the human placenta and fetal growth (review). Mol Med Rep 2012; 5:883-9. [PMID: 22294146 PMCID: PMC3493070 DOI: 10.3892/mmr.2012.763] [Citation(s) in RCA: 112] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2012] [Accepted: 01/24/2012] [Indexed: 12/03/2022] Open
Abstract
Throughout in utero development, the placenta plays a key role in controlling growth and development. The placenta acts not only as a gatekeeper of nutrient and waste exchange between mother and developing fetus, but also as a regulator of the intrauterine environment. Its functions can be influenced by the environment encountered throughout pregnancy, thereby altering the appropriate genetic programming needed to allow for appropriate fetal growth. Epigenetic alterations related to environmental exposures have been linked to aberrant fetal growth. DNA methylation, which is the best known DNA epigenetic modification, may provide an attractive mechanism linking environmental cues to placental pathology, with consequences for fetal growth and adult life. Alteration of the methylation patterns of genes expressed in the placenta has recently been found to modify gene expression and subsequently impair function of the placenta. Although there is strong evidence to demonstrate that the environment can affect the pattern of DNA methylation of the placenta during fetal development, a direct association between environmental conditions, methylation alterations and gene expression is difficult to confirm. DNA methylation in the placenta has mainly been investigated in the context of imprinted and non-imprinted genes transcription. Several environmental factors have also been assessed in regard to their association with changes to the epigenetic motives of embryonic and extraembryonic tissues and their impact on pregnancy outcome. In this review, we briefly present the available evidence regarding the role of DNA methylation patterns of the placenta on aberrant fetal growth.
Collapse
Affiliation(s)
- Ourania Koukoura
- Department of Obstetrics and Gynecology, University Hospital of Larissa, Thessaly, Greece
| | | | | |
Collapse
|
42
|
Yuen RKC, Manokhina I, Robinson WP. Are we ready for DNA methylation-based prenatal testing? Epigenomics 2011; 3:387-90. [PMID: 22126197 DOI: 10.2217/epi.11.62] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Ryan KC Yuen
- Department of Medical Genetics, University of British Columbia, Child & Family Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada
| | - Irina Manokhina
- Department of Medical Genetics, University of British Columbia, Child & Family Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada
| | - Wendy P Robinson
- Department of Medical Genetics, University of British Columbia, Child & Family Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada
| |
Collapse
|
43
|
Vaiman D, Gascoin-Lachambre G, Boubred F, Mondon F, Feuerstein JM, Ligi I, Grandvuillemin I, Barbaux S, Ghigo E, Achard V, Simeoni U, Buffat C. The intensity of IUGR-induced transcriptome deregulations is inversely correlated with the onset of organ function in a rat model. PLoS One 2011; 6:e21222. [PMID: 21731679 PMCID: PMC3120850 DOI: 10.1371/journal.pone.0021222] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2011] [Accepted: 05/23/2011] [Indexed: 01/21/2023] Open
Abstract
A low-protein diet applied during pregnancy in the rat results in intrauterine growth restricted (IUGR) fetuses. In humans, IUGR is associated with increased perinatal morbidity, higher incidence of neuro-developmental defects and increased risk of adult metabolic anomalies, such as diabetes and cardiovascular disease. Development and function of many organs are affected by environmental conditions such as those inducing fetal and early postnatal growth restriction. This phenomenon, termed "fetal programming" has been studied unconnectedly in some organs, but very few studies (if any) have investigated at the same time several organs, on a more comparative basis. However, it is quite probable that IUGR affects differentially most organ systems, with possible persistent changes in gene expression. In this study we address transcriptional alterations induced by IUGR in a multi-organ perspective, by systematic analysis of 20-days rat fetuses. We show that (1) expressional alterations are apparently stronger in organs functioning late in foetal or postnatal life than in organs that are functioning early (2) hierarchical classification of the deregulations put together kidney and placenta in one cluster, liver, lungs and heart in another; (3) the epigenetic machinery is set up especially in the placenta, while its alterations are rather mild in other organs; (4) the genes appear deregulated in chromosome clusters; (5) the altered expression cascades varies from organ to organ, with noticeably a very significant modification of the complement and coagulation cascades in the kidney; (6) we found a significant increase in TF binding site for HNF4 proteins specifically for liver genes that are down-regulated in IUGR, suggesting that this decrease is achieved through the action of HNF transcription factors, that are themselves transcriptionnally induced in the liver by IUGR (x 1.84 fold). Altogether, our study suggests that a combination of tissue-specific mechanisms contributes to bring about tissue-driven modifications of gene cascades. The question of these cascades being activated to adapt the organ to harsh environmental condition, or as an endpoint consequence is still raised.
Collapse
Affiliation(s)
- Daniel Vaiman
- Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Cochin, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|